RU2015130362A - Method and means for preoperative preparation of cancer patients with type 2 diabetes mellitus associated with obesity and cardiovascular disease - Google Patents

Method and means for preoperative preparation of cancer patients with type 2 diabetes mellitus associated with obesity and cardiovascular disease Download PDF

Info

Publication number
RU2015130362A
RU2015130362A RU2015130362A RU2015130362A RU2015130362A RU 2015130362 A RU2015130362 A RU 2015130362A RU 2015130362 A RU2015130362 A RU 2015130362A RU 2015130362 A RU2015130362 A RU 2015130362A RU 2015130362 A RU2015130362 A RU 2015130362A
Authority
RU
Russia
Prior art keywords
obesity
diabetes mellitus
type
cancer patients
cardiovascular disease
Prior art date
Application number
RU2015130362A
Other languages
Russian (ru)
Other versions
RU2623139C2 (en
Inventor
Алексей Юрьевич Добродеев
Валентина Александровна Столярова
Александр Александрович Завьялов
Сергей Александрович Тузиков
Наталия Николаевна Трынченкова
Татьяна Владимировна Саприна
Original Assignee
Федеральное государственное бюджетное научное учреждение "Томский Научно-исследовательский институт онкологии (Томский НИИ онкологии)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное научное учреждение "Томский Научно-исследовательский институт онкологии (Томский НИИ онкологии) filed Critical Федеральное государственное бюджетное научное учреждение "Томский Научно-исследовательский институт онкологии (Томский НИИ онкологии)
Priority to RU2015130362A priority Critical patent/RU2623139C2/en
Publication of RU2015130362A publication Critical patent/RU2015130362A/en
Application granted granted Critical
Publication of RU2623139C2 publication Critical patent/RU2623139C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

1. Применение лекарственного препарата Форсига для предоперационной подготовки онкологических больных с сахарным диабетом 2 типа, ассоциированным с ожирением и сердечно-сосудистой патологией.1. The use of the drug Forsig for the preoperative preparation of cancer patients with type 2 diabetes mellitus associated with obesity and cardiovascular disease. 2. Способ предоперационной подготовки онкологических больных с сахарным диабетом 2 типа, ассоциированным с ожирением и сердечно-сосудистой патологией путем назначения включает проведение фармакотерапии с использованием гипогликемических средств, отличающийся тем, что на фоне проводимого дооперационного комбинированного лечения назначают прием лекарственного препарата Форсига в дозе 10 мг 1 раз в сутки на протяжении трех месяцев до достижения максимальных целевых значений гликемии HbA1C 8% соответственно возраста, соматического состояния и ожидаемой продолжительности жизни больного не более 5 лет.2. The method of preoperative preparation of cancer patients with type 2 diabetes mellitus associated with obesity and cardiovascular pathology by prescribing involves pharmacotherapy using hypoglycemic agents, characterized in that, against the background of the preoperative combined treatment, Forsig is prescribed at a dose of 10 mg 1 time per day for three months until reaching the maximum target glycemia values of HbA 1C 8%, respectively, age, somatic state ia and the expected life expectancy of the patient is not more than 5 years.
RU2015130362A 2015-07-22 2015-07-22 Method and means for preoperative preparation of patients with type 2 diabetes associated with obesity and cardiovascular pathology RU2623139C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015130362A RU2623139C2 (en) 2015-07-22 2015-07-22 Method and means for preoperative preparation of patients with type 2 diabetes associated with obesity and cardiovascular pathology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015130362A RU2623139C2 (en) 2015-07-22 2015-07-22 Method and means for preoperative preparation of patients with type 2 diabetes associated with obesity and cardiovascular pathology

Publications (2)

Publication Number Publication Date
RU2015130362A true RU2015130362A (en) 2017-01-30
RU2623139C2 RU2623139C2 (en) 2017-06-22

Family

ID=58453416

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015130362A RU2623139C2 (en) 2015-07-22 2015-07-22 Method and means for preoperative preparation of patients with type 2 diabetes associated with obesity and cardiovascular pathology

Country Status (1)

Country Link
RU (1) RU2623139C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2028101C1 (en) * 1991-10-22 1995-02-09 Саратовский медицинский институт Method of preoperative preparation of patients with fatness and associated illnesses
RU2090203C1 (en) * 1993-09-10 1997-09-20 Гаркави Любовь Хаимовна Method for treating locally disseminated cancer
RU2526828C1 (en) * 2013-04-30 2014-08-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Method for preoperative correction of respiratory disorders in patients suffering colorectal cancer

Also Published As

Publication number Publication date
RU2623139C2 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
JP2016520089A5 (en)
JP2013525444A5 (en)
NZ601167A (en) Treatment of cardiac conditions
AR086356A1 (en) PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF PATIENTS WHO HAVE TYPE 2 DIABETES
CY1113755T1 (en) LIXISENATIDE AS ADDITIONAL ADMINISTRATION IN INSULIN GARGIN AND METFORMINE FOR TREATMENT TREATMENT OF DIABETIC TYPE 2
EA201792030A1 (en) TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2
JP2017014206A5 (en)
JP2015516419A5 (en)
BR112015004012A2 (en) combinations of sglt 2 inhibitors and antihypertensive drugs
RU2018139578A (en) A method of treating hyperglycemia
JP2017516842A5 (en)
MX2021011711A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease.
RU2015130362A (en) Method and means for preoperative preparation of cancer patients with type 2 diabetes mellitus associated with obesity and cardiovascular disease
TN2017000408A1 (en) Treatment of type 2 diabetes mellitus patients.
RU2018147275A (en) A method for the treatment of type 2 diabetes in patients with steatohepatitis
Rodrigues et al. Mycobacterium Cell Wall Fraction (IMMUNOCIDIN®) for canine transitional cell carcinoma treatment
RU2015148051A (en) A method for the treatment of periodontal disease in patients with type II diabetes
RU2016152653A (en) The use of insulin in the treatment of cats with diabetes
EA202192612A1 (en) CANAGLIFLOSIN FOR THE TREATMENT OF DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE
Lahner Upper gestrointestinal bleeding leading to haemorrhagic shock: case report
汪天湛 Treating type 2 diabetes mellitus patients complicated with metabolic syndrome by benefiting Qi dissolving method
秦树存 Phospholipid transfer protein in diabetes, metabolic syndrome and obesity
Syrigou Hypersensitivity reaction: case report
Turchina et al. Features of the treatment of chronic constipation in an outpatient setting
Ota Interferon-α

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant